Enovix (ENVX) 10-Q 9 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Oct. 01, 2023	Nov. 06, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 01, 2023
Document Transition Report	false
Entity Registrant Name	Enovix Corporation
Entity Incorporation, State or Country Code	DE
Entity File Number	001-39753
Entity Tax Identification Number	85-3174357
Entity Address, Address Line One	3501 W Warren Avenue
Entity Address, City or Town	Fremont
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94538
City Area Code	510
Local Phone Number	695-2350
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ENVX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		167,774,133
Entity Central Index Key	0001828318
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Oct. 01, 2023	Jan. 01, 2023
Current assets:
Cash and cash equivalents	$ 270,817,000	$ 322,851,000
Short-term investments	100,522,000	0
Accounts receivable, net	1,000	170,000
Inventory	215,000	634,000
Deferred contract costs	0	800,000
Prepaid expenses and other current assets	4,182,000	5,193,000
Total current assets	375,737,000	329,648,000
Property and equipment, net	136,713,000	103,868,000
Operating lease, right-of-use assets	5,912,000	6,133,000
Deferred contract costs, non-current	800,000	0
Other assets, non-current	780,000	937,000
Total assets	519,942,000	440,586,000
Current liabilities:
Accounts payable	18,272,000	7,077,000
Accrued expenses	15,784,000	7,089,000
Accrued compensation	9,126,000	8,097,000
Deferred revenue	0	50,000
Other liabilities	944,000	716,000
Total current liabilities	44,126,000	23,029,000
Long-term debt, net	167,080,000	0
Warrant liability	44,940,000	49,080,000
Operating lease liabilities, non-current	7,538,000	8,234,000
Deferred revenue, non-current	3,774,000	3,724,000
Other liabilities, non-current	9,000	92,000
Total liabilities	267,467,000	84,159,000
Commitments and Contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; authorized shares of 1,000,000,000; issued and outstanding shares of 161,665,677 and 157,461,802 as of October 1, 2023 and January 1, 2023, respectively	16,000	15,000
Preferred stock, $0.0001 par value; authorized shares of 10,000,000; no shares issued or outstanding as of October 1, 2023 and January 1, 2023, respectively	0	0
Additional paid-in-capital	791,340,000	741,186,000
Accumulated other comprehensive loss	(13,000)	0
Accumulated deficit	(538,868,000)	(384,774,000)
Total stockholders’ equity	252,475,000	356,427,000
Total liabilities and stockholders’ equity	$ 519,942,000	$ 440,586,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 01, 2023	Jan. 01, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	161,665,677	157,461,802
Common stock, shares outstanding	161,665,677	157,461,802
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Income Statement [Abstract]
Revenue	$ 200,000	$ 8,000	$ 263,000	$ 5,109,000
Cost of revenue	16,809,000	6,629,000	43,292,000	12,883,000
Gross margin	(16,609,000)	(6,621,000)	(43,029,000)	(7,774,000)
Operating expenses:
Research and development	13,508,000	13,948,000	53,810,000	42,506,000
Selling, general and administrative	17,245,000	13,110,000	61,207,000	36,545,000
Impairment of equipment	0	0	4,411,000	0
Restructuring cost	3,021,000	0	3,021,000	0
Total operating expenses	33,774,000	27,058,000	122,449,000	79,051,000
Loss from operations	(50,383,000)	(33,679,000)	(165,478,000)	(86,825,000)
Other income (expense):
Change in fair value of common stock warrants	31,320,000	(50,160,000)	4,140,000	44,040,000
Interest income	4,326,000	1,746,000	9,942,000	2,399,000
Interest expense	(1,557,000)	0	(2,827,000)	0
Other income (expense), net	109,000	80,000	129,000	(55,000)
Total other income (expense), net	34,198,000	(48,334,000)	11,384,000	46,384,000
Net loss	$ (16,185,000)	$ (82,013,000)	$ (154,094,000)	$ (40,441,000)
Net loss per share, basic (in dollars per share)	$ (0.10)	$ (0.53)	$ (0.98)	$ (0.27)
Weighted average number of common shares outstanding, basic (in shares)	159,829,716	153,332,007	157,559,138	152,497,010
Net loss per share, diluted (in dollars per share)	$ (0.29)	$ (0.53)	$ (1)	$ (0.55)
Weighted average number of common shares outstanding, diluted (in shares)	161,371,417	153,332,007	158,260,393	153,773,271

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (16,185)	$ (82,013)	$ (154,094)	$ (40,441)
Other comprehensive income (loss), net of tax
Net unrealized gain (loss) on available-for-sale securities	11	0	(13)	0
Other comprehensive income (loss), net of tax	11	0	(13)	0
Total comprehensive loss	$ (16,174)	$ (82,013)	$ (154,107)	$ (40,441)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Jan. 02, 2022		152,272,287
Beginning balance at Jan. 02, 2022	$ 326,117	$ 15	$ 659,254		$ (333,152)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		91,910
Issuance of common stock upon exercise of stock options	200		200
Issuance of common stock upon exercise of common stock warrants (in shares)		4,126,466
Issuance of common stock upon exercise of common stock warrants	47,452		47,452
Early exercised stock options vested	42		42
RSUs vested (in shares)		34,941
Repurchase of unvested restricted common stock (in shares)		(105,886)
Stock-based compensation	4,536		4,536
Net (loss) income	42,707				42,707
Ending balance (in shares) at Apr. 03, 2022		156,419,718
Ending balance at Apr. 03, 2022	421,054	$ 15	711,484		(290,445)
Beginning balance (in shares) at Jan. 02, 2022		152,272,287
Beginning balance at Jan. 02, 2022	326,117	$ 15	659,254		(333,152)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Change in net unrealized loss on available-for-sale securities, net of tax	0
Net (loss) income	(40,441)
Ending balance (in shares) at Oct. 02, 2022		157,077,599
Ending balance at Oct. 02, 2022	358,283	$ 15	731,861		(373,593)
Beginning balance (in shares) at Apr. 03, 2022		156,419,718
Beginning balance at Apr. 03, 2022	421,054	$ 15	711,484		(290,445)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		46,807
Issuance of common stock upon exercise of stock options	77		77
Issuance of common stock under employee stock purchase plan (in shares)		126,574
Issuance of common stock under employee stock purchase plan	1,113		1,113
Early exercised stock options vested	28		28
RSUs vested (in shares)		115,990
Repurchase of unvested restricted common stock (in shares)		(30,399)
Stock-based compensation	7,603		7,603
Net (loss) income	(1,135)				(1,135)
Ending balance (in shares) at Jul. 03, 2022		156,678,690
Ending balance at Jul. 03, 2022	428,740	$ 15	720,305		(291,580)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		204,483
Issuance of common stock upon exercise of stock options	1,775		1,775
Early exercised stock options vested	28		28
RSUs vested (in shares)		209,156
Repurchase of unvested restricted common stock (in shares)		(14,730)
Stock-based compensation	9,753		9,753
Change in net unrealized loss on available-for-sale securities, net of tax	0
Net (loss) income	(82,013)				(82,013)
Ending balance (in shares) at Oct. 02, 2022		157,077,599
Ending balance at Oct. 02, 2022	$ 358,283	$ 15	731,861		(373,593)
Beginning balance (in shares) at Jan. 01, 2023	157,461,802	157,461,802
Beginning balance at Jan. 01, 2023	$ 356,427	$ 15	741,186	$ 0	(384,774)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		86,654
Issuance of common stock upon exercise of stock options	328		328
Early exercised stock options vested	83	$ 1	82
RSUs vested, net of shares withheld for taxes (in shares)		679,606
RSUs vested, net of shares withheld for taxes	(777)		(777)
Repurchase of unvested restricted common stock (in shares)		(138,599)
Stock-based compensation	29,653		29,653
Net (loss) income	(73,603)				(73,603)
Ending balance (in shares) at Apr. 02, 2023		158,089,463
Ending balance at Apr. 02, 2023	$ 312,111	$ 16	770,472	0	(458,377)
Beginning balance (in shares) at Jan. 01, 2023	157,461,802	157,461,802
Beginning balance at Jan. 01, 2023	$ 356,427	$ 15	741,186	0	(384,774)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	1,135,249
Change in net unrealized loss on available-for-sale securities, net of tax	$ (13)
Net (loss) income	$ (154,094)
Ending balance (in shares) at Oct. 01, 2023	161,665,677	161,665,677
Ending balance at Oct. 01, 2023	$ 252,475	$ 16	791,340	(13)	(538,868)
Beginning balance (in shares) at Apr. 02, 2023		158,089,463
Beginning balance at Apr. 02, 2023	312,111	$ 16	770,472	0	(458,377)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		93,921
Issuance of common stock upon exercise of stock options	643		643
Issuance of common stock under employee stock purchase plan (in shares)		146,278
Issuance of common stock under employee stock purchase plan	1,170		1,170
Early exercised stock options vested	14		14
RSUs vested, net of shares withheld for taxes (in shares)		650,202
RSUs vested, net of shares withheld for taxes	(448)		(448)
Repurchase of unvested restricted common stock (in shares)		(68,445)
Stock-based compensation	15,374		15,374
Purchase of Capped Calls	(17,250)		(17,250)
Change in net unrealized loss on available-for-sale securities, net of tax	(24)			(24)
Net (loss) income	(64,306)				(64,306)
Ending balance (in shares) at Jul. 02, 2023		158,911,419
Ending balance at Jul. 02, 2023	247,284	$ 16	769,975	(24)	(522,683)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		954,674
Issuance of common stock upon exercise of stock options	8,260		8,260
Issuance of common stock subject to return (in shares)		1,304,954
Early exercised stock options vested	22		22
RSUs vested, net of shares withheld for taxes (in shares)		656,367
RSUs vested, net of shares withheld for taxes	(1,762)		(1,762)
Repurchase of unvested restricted common stock (in shares)		(161,737)
Stock-based compensation	14,845		14,845
Change in net unrealized loss on available-for-sale securities, net of tax	11			11
Net (loss) income	$ (16,185)				(16,185)
Ending balance (in shares) at Oct. 01, 2023	161,665,677	161,665,677
Ending balance at Oct. 01, 2023	$ 252,475	$ 16	$ 791,340	$ (13)	$ (538,868)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022
Cash flows from operating activities:
Net loss	$ (154,094,000)	$ (40,441,000)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	10,566,000	4,388,000
Amortization of right-of-use assets	436,000	407,000
Accretion of discount on investments	(1,499,000)	0
Amortization of debt issuance costs	497,000	0
Stock-based compensation	57,832,000	22,117,000
Changes in fair value of common stock warrants	(4,140,000)	(44,040,000)
Impairment of equipment	4,411,000	0
Changes in operating assets and liabilities:
Accounts receivable	169,000	(6,000)
Inventory	418,000	(452,000)
Prepaid expenses and other assets	546,000	(2,004,000)
Deferred contract costs	0	3,015,000
Accounts payable	4,338,000	(192,000)
Accrued expenses and compensation	3,113,000	(122,000)
Deferred revenue	0	(3,527,000)
Other liabilities	(1,000)	(46,000)
Net cash used in operating activities	(77,408,000)	(60,903,000)
Cash flows from investing activities:
Purchase of property and equipment	(32,979,000)	(31,366,000)
Purchases of investments	(115,736,000)	0
Maturities of investments	16,700,000	0
Net cash used in investing activities	(132,015,000)	(31,366,000)
Cash flows from financing activities:
Proceeds from exercise of common stock warrants, net	0	52,828,000
Proceeds from issuance of Convertible Senior Notes	172,500,000	0
Payments of debt issuance costs	(5,251,000)	0
Purchase of Capped Calls	(17,250,000)	0
Payroll tax payments for shares withheld upon vesting of RSUs	(2,988,000)	0
Proceeds from the exercise of stock options	9,232,000	2,052,000
Proceeds from issuance of common stock under employee stock purchase plan	1,169,000	1,112,000
Repurchase of unvested restricted common stock	(23,000)	(9,000)
Net cash provided by financing activities	157,389,000	55,983,000
Change in cash, cash equivalents, and restricted cash	(52,034,000)	(36,286,000)
Cash and cash equivalents and restricted cash, beginning of period	322,976,000	385,418,000
Cash and cash equivalents, and restricted cash, end of period	270,942,000	349,132,000
Supplemental cash flow data (Non-cash):
Purchase of property and equipment included in liabilities	19,324,000	4,689,000
Accrued acquisition costs	1,115,000	0
Accrued debt issuance costs	$ 666,000	$ 794,000

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Oct. 01, 2023	Oct. 02, 2022
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 270,817	$ 349,007
Restricted cash included in prepaid expenses and other current assets	125	125
Total cash, cash equivalents, and restricted cash	$ 270,942	$ 349,132

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Oct. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Organization Enovix Corporation (“Enovix” or the “Company”) was incorporated in Delaware in 2006. The Company designs, develops, manufactures and commercializes next generation Lithium-ion, or Li-ion, battery cells that significantly increase the amount of energy density and storage capacity relative to conventional battery cells. Our batteries’ mechanical design, or “architecture,” allows us to use high performance chemistries while enabling safety and charge time advantages. The Company is headquartered in Fremont, California. Prior to the second quarter of 2022, the Company was focused on the development and commercialization of its silicon-anode lithium-ion batteries. Beginning in the second quarter of 2022, the Company commenced its planned principal operations of commercial manufacturing and began its production of silicon-anode lithium-ion batteries or battery pack products, as well as generating product revenue in addition to service revenue from its engineering service contracts for the development of silicon-anode lithium-ion battery technology.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 01, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States (“GAAP”). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company did not have any income tax expenses for the periods presented. Liquidity and Capital Resources The Company has incurred operating losses and negative cash flows from operations since its inception through October 1, 2023 and expects to incur operating losses for the foreseeable future. As of October 1, 2023, the Company had a working capital of $331.6 million and an accumulated deficit of $538.9 million. In April 2023, we closed private offerings of $172.5 million aggregate principal amount of 3.0% convertible senior notes due 2028 (the “Convertible Senior Notes”). The net proceeds from the Convertible Senior Notes were approximately $166.6 million. The Company used approximately $17.3 million of the net proceeds from the offerings of the Convertible Senior Notes to pay the cost of the capped call transactions entered on April 20, 2023 in connection with such offerings. The Company will use the remaining net proceeds to build out a second battery cell manufacturing facility (“Fab2”) in Malaysia and fund the acquisition of production lines of the Company’s second-generation (“Gen2”) manufacturing equipment (“Gen2 Autolines”), and for working capital and other general corporate purposes. See Note 7 “Borrowings” for more information. Based on the anticipated spending and timing of expenditures, the Company currently expects that its cash will be sufficient to meet its funding requirements over the next twelve months. Going forward, the Company may require additional financing for its future operations and expansion. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Unaudited Interim Condensed Consolidated Financial Statements The Condensed Consolidated Balance Sheet as of October 1, 2023, the Condensed Consolidated Statements of Operations, the Condensed Consolidated Statement of Comprehensive Income, the Condensed Consolidated Statements of Changes in Shareholders’ Equity and the Condensed Consolidated Statements of Cash Flows for the quarters and fiscal years-to-date ended October 1, 2023 and October 2, 2022 are unaudited. These accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC for interim financial reporting. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring items, considered necessary to present fairly the Company’s financial condition, results of operations, stockholders’ equity and cash flows for the periods presented above. The results of operations for the quarter and year-to-date ended October 1, 2023 are not necessarily indicative of the operating results for the full year, and therefore should not be relied upon as an indicator of future results. The Condensed Consolidated Balance Sheet as of January 1, 2023 included herein was derived from the audited consolidated financial statements as of that date and the accompanying consolidated financial statements and related notes are included in the Company’s Annual Report on Form 10-K. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the condensed consolidated financial statements and accompanying notes during the reporting periods. Estimates and assumptions include but are not limited to: depreciable lives for property and equipment, valuation for inventory, the valuation allowance on deferred tax assets, assumptions used in stock-based compensation, incremental borrowing rate for operating right-of-use assets and lease liabilities, and estimates to fair value common stock warrants. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Summary of Significant Accounting Policies Beginning in May 2023, the Company invested in marketable securities from time to time. In addition, during the third quarter of 2023, the Company acquired variable interests in a legal entity, which is considered as a variable interest entity (“VIE”), in connection with building out the Fab2 operations in Malaysia. For the assessment of the Company’s VIE, please refer to Note 13 “Variable Interest Entity” for more details. As a result of these activities, the Company made the following updates to the significant accounting policies disclosed in Note 2 “Summary of Significant Accounting Policies,” of the notes to the consolidated financial statements for the fiscal year ended January 1, 2023, included in the Company’s Annual Report on Form 10-K. Investments The Company’s investments consist of highly liquid fixed-income securities. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its investments as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, including prior to maturity. Investments with original maturities greater than 90 days and remaining maturities of less than one year are normally classified within current assets on the Condensed Consolidated Balance Sheets. In addition, investments with maturities beyond one year at the time of purchase that are highly liquid in nature and represent the investment of cash that is available for current operations are classified as current assets. Unrealized gains and losses on these investments are reported as a separate component of Accumulated other comprehensive loss until the security is sold, the security has matured, or the security has realized. Realized gains and losses on these investments are calculated based on the specific identification method and would be reclassified from Accumulated other comprehensive loss to Other income (expense), net in the Condensed Consolidated Statements of Operations. The Company has designated all investments as available-for-sale and, therefore, the investments are subject to periodic impairment under the available-for-sale debt security impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to Other income (expense), net in the Condensed Consolidated Statements of Operations if the Company intends to sell the security or it is more likely than not the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected credit losses. A decline in fair value attributable to expected credit losses is recorded to Other income (expense), net, while any portion of the loss related to non-credit factors is recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in Other income (expense), net in the Condensed Consolidated Statements of Operations. Variable Interest Entity The Company determines at the inception of each arrangement whether an entity in which the Company holds an investment or in which the Company has other variable interests is considered a VIE. The Company consolidates the VIE’s balance sheet and results of operations into its condensed consolidated financials when the Company deems to be the primary beneficiary that meets both of the following criteria: (1) the Company has the power to direct activities that most significantly affect the VIE’s economic performance and (2) the Company has the obligation to absorb losses or the right to receive benefits of the VIE that in either case could potentially be significant to the VIE. The Company continually reassesses whether the Company is the primary beneficiary of a VIE for the consolidation analysis. If the Company is not the primary beneficiary in a VIE, the Company accounts for the investment or other variable interest in accordance with applicable GAAP. Please refer to Note 13 “Variable Interest Entity” for more details. The Company will reconsider whether the entity is still a VIE if certain reconsideration events occur as defined in the Accounting Standards Codification (“ASC”) 810, Consolidation, issued by the Financial Accounting Standards Board (“FASB”). Foreign Currency Transactions The functional currency of the Company’s international subsidiaries is the U.S. dollar. Monetary assets and liabilities of the Company's international subsidiaries that are denominated in foreign currency are remeasured into U.S. dollars at period-end exchange rates. Non-monetary assets and liabilities that are denominated in the foreign currency are remeasured into U.S. dollars at the historical rates. Foreign transaction gains and losses resulting from the conversion of the transaction currency to functional currency and remeasurement of foreign currency accounts are reflected in Other income (expense), net of the Condensed Consolidated Statements of Operations. For the quarter and fiscal year-to-date ended October 1, 2023, the Company recorded an immaterial amount of net foreign transaction gains in Other income (expense), net of the Condensed Consolidated Statements of Operations.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Oct. 01, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The fair value of the Company’s financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820, Fair Value Measurements, issued by the FASB. The fair value hierarchy of ASC 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels: Level 1: Observable inputs, such as quoted prices (unadjusted) in active markets for identical assets or liabilities at the measurement date. Level 2: Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and warrant liabilities. Cash and cash equivalents are reported at their respective fair values on the Company's Condensed Consolidated Balance Sheets. The following table details the fair value measurements of assets and liabilities that were measured at fair value on a recurring basis based on the following three-tiered fair value hierarchy per ASC 820, Fair Value Measurement , as of October 1, 2023 and January 1, 2023 (in thousands). Fair Value Measurement using Level 1 Level 2 Level 3 Total As of October 1, 2023 Assets: Cash equivalents: Money Market Funds $ 29,259 $ — $ — $ 29,259 Short-term investments: U.S. Treasuries — 100,522 — 100,522 Liabilities: Private Placement Warrants $ — $ — $ 44,940 $ 44,940 As of January 1, 2023 Assets: Cash equivalents: Money Market Funds $ 319,946 $ — $ — $ 319,946 Liabilities: Private Placement Warrants $ — $ — $ 49,080 $ 49,080 Cash Equivalents and Short-term Investments: The following is a summary of cash equivalents and short-term investments (in thousands). Reported as Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Cash Equivalents Short-term Investments As of October 1, 2023 Money Market Funds $ 29,259 $ — $ — $ 29,259 $ 29,259 $ — U.S. Treasuries 100,535 2 (15) 100,522 — 100,522 Total $ 129,794 $ 2 $ (15) $ 129,781 $ 29,259 $ 100,522 As of January 1, 2023 Money Market Funds $ 319,946 $ — $ — $ 319,946 $ 319,946 $ — As of October 1, 2023, the short-term investments have contractual maturity due within one year. Private Placement Warrants The Company’s liabilities are measured at fair value on a recurring basis, including 6,000,000 warrants that were held by Rodgers Capital, LLC (the “Sponsor”) and certain of its members (the “Private Placement Warrants”). The fair value of the Private Placement Warrants is considered a Level 3 valuation and is determined using the Black-Scholes valuation model. As of October 1, 2023, the fair value of the Private Placement Warrants was $7.49 per share with an exercise price of $11.50 per share. The following tables summarize the changes for Level 3 items measured at fair value on a recurring basis using significant unobservable inputs (in thousands). Private Placement Warrants Fair value as of January 1, 2023 $ 49,080 Change in fair value (4,140) Fair value as of October 1, 2023 $ 44,940 Private Placement Warrants Fair value as of January 2, 2022 $ 124,260 Change in fair value (44,040) Fair value as of October 2, 2022 $ 80,220 The following table summarizes the key assumptions used for determining the fair value of the Private Placement warrants. Private Placement Warrants Outstanding as of October 1, 2023 Private Placement Warrants Outstanding as of January 1, 2023 Expected term (in years) 2.8 3.5 Expected volatility 90.0% 92.5% Risk-free interest rate 4.8% 4.2% Expected dividend rate 0.0% 0.0% Convertible Senior Notes The Company considers the fair value of the Convertible Senior Notes to be a Level 2 measurement as they are not actively traded in the market. As of October 1, 2023, the fair value of the Convertible Senior Notes was $183.3 million.

Property and Equipment

Property and Equipment	9 Months Ended
	Oct. 01, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. Property and equipment as of October 1, 2023 and January 1, 2023, consisted of the following (in thousands). October 1, 2023 January 1, 2023 Machinery and equipment $ 74,565 $ 55,694 Office equipment and software 2,412 1,586 Furniture and fixtures 829 771 Leasehold improvements 30,012 24,565 Construction in process 49,956 33,268 Total property and equipment 157,774 115,884 Less: accumulated depreciation (21,061) (12,016) Property and equipment, net $ 136,713 $ 103,868 The following table summarizes the depreciation and amortization expenses related to property and equipment, which are recorded within cost of revenue, research and development expense and selling, general and administrative expense in the Condensed Consolidated Statements of Operations (in thousands). Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Depreciation expense $ 3,588 $ 2,857 $ 10,566 $ 4,388 Equipment Impairment During the second quarter of 2023, the Company disposed a group of machinery and equipment and recorded an impairment charge of $4.4 million. There was no impairment charge recorded in the quarter ended October 1, 2023 and the impairment charge for the fiscal year-to-date ended October 1, 2023 was $4.4 million. As of October 1, 2023 and January 1, 2023, $0.6 million and $1.7 million of the impairment charges, respectively, were recorded as accrued expenses on the Condensed Consolidated Balance Sheet. These impaired assets were previously capitalized as “Machinery and equipment” category of property and equipment, net on the Condensed Consolidated Balance Sheets. No impairment of equipment was recorded for the corresponding periods in the prior year.

Inventory

Inventory	9 Months Ended
	Oct. 01, 2023
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value (“NRV”) on a first-in and first-out basis. Cost includes materials, labor, and normal manufacturing overhead related to the purchase and production of inventories. The Company values its inventory periodically to the lower of cost or NRV and records the difference to cost of revenue. Inventory consists of the following components (in thousands). October 1, 2023 January 1, 2023 Raw materials $ — $ 481 Work-in-process 15 106 Finished goods 200 47 Total inventory $ 215 $ 634 In connection with the restructuring plan as described in the Note 15 “Restructuring Costs,” the Company wrote off $0.6 million of raw materials as Restructuring cost in the Condensed Consolidated Statements of Operations for the quarter and fiscal year-to-day ended October 1, 2023. There was no write-off of inventory recorded for the corresponding periods in the prior year.

Leases

Leases	9 Months Ended
	Oct. 01, 2023
Leases [Abstract]
Leases	Leases The Company leases its headquarters, engineering and manufacturing space in Fremont, California under a single non-cancellable operating lease with an expiration date of August 31, 2030. In March 2021, the Company entered into a new agreement to lease office space in Fremont, California under a non-cancellable operating lease that expires in April 2026 with an option to extend for five years. The components of lease costs were as follows (in thousands): Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Operating lease cost $ 478 $ 453 $ 1,428 $ 1,292 Supplemental lease information: As of Operating leases October 1, 2023 January 1, 2023 Weighted-average remaining lease term 6.9 years 7.7 years Weighted-average discount rate 6.8% 6.8% Supplemental cash flow information related to leases are as follows (in thousands): Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,053 $ 1,022 Maturities of Lease Liabilities The following is a schedule of maturities of lease liabilities as of October 1, 2023 (in thousands). Operating lease 2023 (remaining six months) $ 353 2024 1,449 2025 1,492 2026 1,491 2027 1,513 Thereafter 4,262 Total 10,560 Less: imputed interest (2,111) Present value of lease liabilities $ 8,449

Net Loss per Share

Net Loss per Share	9 Months Ended
	Oct. 01, 2023
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The following table sets forth the computation of the Company’s basic and diluted net EPS of common stock for the periods presented below (in thousands, except share and per share amount). Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Numerator: Net loss attributable to common stockholders - basic $ (16,185) $ (82,013) $ (154,094) $ (40,441) Decrease in fair value of Private Placement Warrants (31,320) — (4,140) (44,040) Net loss attributable to common stockholders - diluted $ (47,505) $ (82,013) $ (158,234) $ (84,481) Denominator: Weighted-average shares outstanding used in computing net loss per share of common stock, basic 159,829,716 153,332,007 157,559,138 152,497,010 Dilutive effect of Private Placement Warrants 1,541,701 — 701,255 1,276,261 Weighted-average shares outstanding used in computing net loss per share of common stock, diluted 161,371,417 153,332,007 158,260,393 153,773,271 Net loss per share of common stock: Basic $ (0.10) $ (0.53) $ (0.98) $ (0.27) Diluted $ (0.29) $ (0.53) $ (1.00) $ (0.55) The following table discloses shares of the securities that were not included in the diluted EPS calculation above because they are anti-dilutive for the periods presented above. Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Stock options outstanding 3,075,138 5,083,643 3,075,138 5,083,643 Restricted stock units and performance restricted stock units outstanding 12,602,239 5,933,914 12,602,239 5,933,914 Assumed conversion of Convertible Senior Notes 11,053,800 — 6,608,868 — Private Placement Warrants outstanding — 6,000,000 — — Employee stock purchase plan estimated shares 243,474 380,847 243,474 380,847

Borrowings

Borrowings	9 Months Ended
	Oct. 01, 2023
Debt Disclosure [Abstract]
Borrowings	Borrowings The Company’s long-term debt, net consists of the following (in thousands). Annual Interest Rate Maturity Date As of October 1, 2023 Convertible Senior Notes 3.0 % May 1, 2028 $ 172,500 Less: unamortized debt issuance costs (5,420) Long-term debt, net $ 167,080 Convertible Senior Notes On April 20, 2023, the Company issued $172.5 million aggregate principal amount of Convertible Senior Notes, pursuant to an indenture, dated as of April 20, 2023 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). The offerings and sale of the Convertible Senior Notes were made by the Company to the initial purchasers in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), for resale by the initial purchasers to qualified institutional buyers (as defined in the Securities Act) pursuant to the exemption from registration provided by Rule 144A under the Securities Act. The issuance included the exercise in full by the initial purchasers of their option to purchase an additional $22.5 million aggregate principal amount of the Convertible Senior Notes. $10.0 million principal amount of the Convertible Senior Notes (the “Affiliate Notes”) were issued to an entity affiliated with Thurman John “T.J.” Rodgers, the Company’s Chairman in a concurrent private placement. The Convertible Senior Notes are unsecured obligations of the Company and bear interest at a rate of 3.0% per year from April 20, 2023, and will be payable semiannually in arrears on May 1 and November 1 of each year, beginning on November 1, 2023. The Convertible Senior Notes will mature on May 1, 2028 unless earlier converted, redeemed or repurchased. The net proceeds from the offerings were approximately $166.6 million. The Company used approximately $17.3 million of the net proceeds from the offerings to pay the cost of the capped call transactions entered on April 20, 2023 in connection with the offerings. The Company will use the remaining net proceeds to build out Fab2 in Malaysia and fund the acquisition of Gen2 Autolines, and for working capital and other general corporate purposes. The conversion rate for the Convertible Senior Notes will initially be 64.0800 shares of the Company’s common stock per $1,000 principal amount of the Convertible Senior Notes, which is equivalent to an initial conversion price of $15.61 per share of common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. Holders of the Convertible Senior Notes may convert all or any portion of their notes, in integral multiples of $1,000 principal amount, at their option at any time prior to the close of business on the business day immediately preceding February 1, 2028 only under the following conditions: • during any fiscal quarter commencing after the fiscal quarter ending on October 1, 2023 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the “trading price” (as defined in the Indenture) per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; • if the Company calls the Convertible Senior Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Convertible Senior Notes called (or deemed called) for redemption; or • upon the occurrence of specified corporate events as set forth in the Indenture. On or after February 1, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their notes, at any time, in integral multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. The Company may not redeem the Convertible Senior Notes prior to May 6, 2026. The Company may redeem for cash all or any portion of the Convertible Senior Notes, at its option, on or after May 6, 2026, if the liquidity condition is satisfied and the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeem less than all the outstanding notes, at least $100.0 million aggregate principal amount of notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant redemption notice. If the Company undergoes a “fundamental change,” as defined in the Indenture, fundamental change permits the holders of the Convertible Senior Notes to require the Company to repurchase the Convertible Senior Notes, subject to certain terms and conditions as defined in the Indenture. Holders may require the Company to repurchase for cash all or any portion of their notes in principal amounts of $1,000 or an integral multiple thereof. The fundamental change repurchase price will be equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In accounting for the issuance of the Convertible Senior Notes, the Company accounted for the Convertible Senior Notes as liability instruments and considered it as single units of account pursuant to the Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) , (“ASU 2020-06”). Accrued interest for the Convertible Senior Notes was recorded as Accrued expenses on the Condensed Consolidated Balance Sheet. Costs incurred in connection with the issuance of debt are deferred and amortized as interest expense over the term of the related debt using the effective interest method. To the extent that the debt is outstanding, the debt issuance costs were recorded as a reduction to Long-term debt, net on the Condensed Consolidated Balance Sheet. For the fiscal year-to-date ended October 1, 2023, the Company incurred approximately $5.9 million of debt issuance costs relating to the issuance of the Convertible Senior Notes. There was no debt issuance cost recorded for the quarter ended October 1, 2023. The following table summarizes the interest expenses related to Convertible Senior Notes, which are recorded within Interest expense in the Condensed Consolidated Statements of Operations (in thousands). October 1, 2023 Quarter Ended Fiscal Year-to-Date Ended Coupon interest $ 1,283 $ 2,326 Amortization of debt issuance costs 275 497 Total interest expense on Convertible Senior Notes $ 1,558 $ 2,823 As of October 1, 2023, the Company had $2.3 million of accrued interest liability. There was no accrued interest liability as of January 1, 2023. Capped Call Transactions In connection with the issuance of the Convertible Senior Notes , the Company paid approximately $17.3 million to enter into capped call transactions with certain financial institutions (the “Capped Calls”) in the second quarter of 2023. The Capped Calls are generally expected to reduce the potential dilution to the Company's common stock upon any conversion of the Convertible Senior Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of the converted Convertible Senior Notes , as the case may be, with such reduction and/or offset subject to a cap based on a cap price initially equal to $21.17 per share (which represents a premium of 56.0% over the last reported sale price of the Company's common stock of $13.57 per share on The Nasdaq Global Select Market on April 17, 2023), and is subject to certain adjustments under the terms of the Capped Calls. The Company recorded the Capped Calls

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 01, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of October 1, 2023 and January 1, 2023, the Company’s commitments included approximately $73.7 million and $22.7 million, respectively, of the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures and construction-related activities for which the Company has not received the services. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or performance of services. For lease obligations, please refer to Note 6 “Leases” for more details. For the Convertible Senior Notes obligation, please refer to Note 7 “Borrowings” for more details. Performance Obligations As of October 1, 2023, the Company had $3.8 million of performance obligations, which comprised of total deferred revenue and customer order deposits. Currently, the Company does not expect to recognize revenue from deferred revenue within the next twelve months. Litigation From time to time, the Company is involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, intellectual property, commercial, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. The Company intends to defend vigorously against all of the following allegations. A liability and related charge to earnings are recorded in the condensed consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including the impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. The outcomes of outstanding legal matters are inherently unpredictable and subject to uncertainties. While there can be no assurance of favorable outcome of these legal matters, we currently believe that the outcome of these matters will not have a material adverse effect on the Company’s results of operations, liquidity or financial position. Sopheap Prak et al. v. Enovix Corporation et al., 22CV005846, Superior Court of California, Alameda County On January 21, 2022, two former machine operator employees filed a putative wage and hour class action lawsuit against Enovix and co-defendant Legendary Staffing, Inc. in the Superior Court of California, County of Alameda. The case is captioned Sopheak Prak & Ricardo Pimentel v Enovix Corporation and Legendary Staffing, Inc. , 22CV005846. The Prak complaint alleges, among other things, on a putative class-wide basis, that the defendants failed to pay all overtime wages and committed meal period, rest period and wage statement violations under the California Labor Code and applicable Wage Orders. The plaintiffs are seeking unpaid wages, statutory penalties and interest and reasonable costs and attorney fees. In September 2022, the Company began the mediation process. Based on the current knowledge of the legal proceeding, an estimate of possible loss liability was recorded on the Condensed Consolidated Balance Sheet as of October 1, 2023 . Kody Walker v. Enovix Corporation, 23CV028923. Superior Court of California, Alameda County On March 8, 2023, a former employee filed a putative class action lawsuit against Enovix in the Superior Court of California, County of Alameda (the “Walker Complaint”). The Walker Complaint alleges, among other things, on a putative class-wide basis, that the Company failed to pay minimum wages, overtime and sick time wages, failed to reimburse employees for required expenses, failed to provide meal and rest periods and issued inaccurate wage statement under the California Labor Code and applicable Wage Orders. The Walker Complaint asserts on an individual basis that Walker was constructively discharged. The plaintiff seeks unpaid wages, statutory penalties and interest and reasonable costs and attorney fees. Securities Class Action Compliant On January 6, 2023, a purported Company stockholder filed a securities class action complaint in the U.S. District Court for the Northern District of California against the Company and certain of its current and former officers and directors. The complaint alleges that defendants violated Sections 10(b) and 20(a) of the Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making material misstatements or omissions in public statements related to the Company’s manufacturing scaleups and testing of new equipment. A substantially identical complaint was filed on January 25, 2023 by another purported Company stockholder. Following consolidation of the cases and court appointment of two purported Company stockholder lead plaintiffs, a consolidated complaint alleging substantially similar claims, including allegations that the defendants made material misstatements or omissions in public statements related to testing of new equipment, was filed on July 7, 2023. The consolidated complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of the Company or RSVAC’s common stock between June 24, 2021 and January 3, 2023. The Company and the named officers and directors moved to dismiss the complaint on September 15, 2023. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter. Guarantees and Indemnifications In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its officers and directors for specified events or occurrences, subject to some limits, while they are serving at the Company’s request in such capacities. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities relating to these obligations for the period presented.

Warrants

Warrants	9 Months Ended
	Oct. 01, 2023
Other Liabilities Disclosure [Abstract]
Warrants	Warrants Common Stock Warrants On July 14, 2021, Enovix Corporation, a Delaware Corporation, Rodgers Silicon Valley Acquisition Corp. (“RSVAC”), and RSVAC Merger Sub Inc., a Delaware Corporation and wholly owned subsidiary of RSVAC, consummated the closing of the transactions contemplated by the Agreement and Plan of Merger, dated February 22, 2021 (the “Business Combination”). In connection with the Business Combination in July 2021, the Company assumed 17,500,000 common stock warrants outstanding, which consisted of 11,500,000 warrants held by third-party investors (the “Public Warrants”) and 6,000,000 Private Placement Warrants. The Public Warrants met the criteria for equity classification and the Private Placement Warrants are classified as liability. In the first quarter of fiscal year 2022, the Public Warrants were either exercised or redeemed. As of October 1, 2023 and January 1, 2023, there were no Public Warrants outstanding. Private Placement Warrants The 6,000,000 Private Placement Warrants were originally issued in a private placement to the initial stockholder of the Sponsor in connection with the initial public offering of RSVAC. Each whole Private Placement Warrant became exercisable for one whole share of the Company's common stock at a price of $11.50 per share on December 5, 2021. As of October 1, 2023 and January 1, 2023, the Company had 6,000,000 Private Placement Warrants outstanding. See Note 3 “Fair Value Measurement” for more information.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Oct. 01, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based CompensationThe Company issues equity awards to employees and non-employees in the form of stock options, restricted stock units (“RSUs”) and performance based RSUs (“PRSUs”). Additionally, the Company also offers an employee stock purchase plan (“ESPP”) to its eligible employees. The Company uses Black-Scholes option pricing model to value its stock options granted and the estimated shares to be purchased under the ESPP. For both RSUs and PRSUs, the Company uses its common stock price, which is the last reported sales price on the grant date to value those securities. In general, the Company recognizes its stock-based compensation expense on a straight-line basis over the requisite service period and records forfeitures as they occur. For PRSUs, the Company uses the graded vesting method to calculate the stock-based compensation expense. At each reporting period, the Company would recognize and adjust the stock-based compensation expense based on its probability assessment in meeting its PRSUs' performance conditions. Stock-based Compensation Expense The following table summarizes the total stock-based compensation expense, by operating expense category, recognized in the Condensed Consolidated Statements of Operations for the periods presented below (in thousands). Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Cost of revenue $ 2,396 $ 1,067 $ 5,001 $ 1,317 Research and development 4,949 3,372 22,072 9,705 Selling, general and administrative 5,929 4,260 30,400 11,095 Restructuring cost 359 — 359 — Total stock-based compensation expense $ 13,633 $ 8,699 $ 57,832 $ 22,117 For the fiscal years-to-date ended October 1, 2023 and October 2, 2022, the Company capitalized $0.8 million and $1.2 million, respectively, of stock-based compensation as property and equipment, net on the Condensed Consolidated Balance Sheet. There was no recognized tax benefit related to stock-based compensation for the periods presented. In addition, the Company accrued an immaterial amount of bonus to be settled in equity awards as accrued compensation on the Condensed Consolidated Balance Sheet as of October 1, 2023. As of October 1, 2023, there was approximately $140.1 million of total unrecognized stock-based compensation expense related to unvested equity awards, which are expected to be recognized over a weighted-average period of 3.9 years. As of October 1, 2023, there was approximately $0.5 million of total unrecognized stock-based compensation related to the ESPP, which is expected to be recognized over a period of 1.1 years. Equity Award Modification For the first quarter of 2023, in connection with the retirement or resignation of several of the Company's management team members, including the Company's former Chief Executive Officer, the Company evaluated the change in employment status in accordance with ASC 718, Compensation - Stock Compensation . The Company concluded that the change in status impacted the vesting conditions as the term of equity award exercise period was extended and certain of the equity awards were accelerated and vested immediately. For the quarter ended October 1, 2023, there was no equity award modification. For the fiscal year-to-date ended October 1, 2023, the Company recognized $21.1 million of stock-based compensation expense related to the modifications. There is no equity modification occurred for the corresponding period last year. Stock Option Activity The following table summarizes stock option activities for the fiscal year-to-date ended October 1, 2023 (in thousands, except share and per share amount). Number of Weighted Weighted Aggregate Intrinsic Value (1) (2) Balances as of January 1, 2023 5,034,282 $ 9.07 Exercised (1,135,249) 8.13 $ 13,446 Forfeited (823,895) 9.20 Balances as of October 1, 2023 3,075,138 $ 9.39 7.5 $ 11,166 (1) The intrinsic value of options exercised is based upon the value of the Company’s stock at exercise. (2) The aggregate intrinsic value of the stock options outstanding as of October 1, 2023 represents the value of the Company’s closing stock price at $12.55 on the last trading day of the quarter ended October 1, 2023 in excess of the exercise price multiplied by the number of options outstanding. Unvested early exercised stock options which are subject to repurchase by the Company are not considered participating securities as those shares do not have non-forfeitable rights to dividends or dividend equivalents. Unvested early exercised stock options are not considered outstanding for purposes of the weighted average outstanding share calculation until they vest. As of October 1, 2023, 657,981 shares remained subject to the Company’s right of repurchase as a result of early exercised stock options. The remaining liability related to early exercised shares as of October 1, 2023 was immaterial and was recorded in other current and non-current liabilities in the Condensed Consolidated Balance Sheets. Issuance of Common Stock Subject to Return In connection with certain early exercised stock options, during the quarter ended October 1, 2023, the Company’s transfer agent erroneously issued an additional 1.3 million shares of common stock to several former executive officers as a result of an administrative issue. Based on the Company’s review and assessment as of October 1, 2023, the Company’s loss associated with this common stock issuance was approximately $22.4 million. Currently, the Company expects a full recovery of these common stock shares from the former executive officers. Both the issuance of these shares related to the loss and the corresponding receivable from the probable recovery were recorded as additional paid-in capital on the Condensed Consolidated Balance Sheet as of October 1, 2023. The loss amount and the offsetting probable recovery amount resulted in no impact to the Condensed Consolidated Statement of Operations for the quarter and fiscal year-to-date ended October 1, 2023. This estimate is based on the current known information available, which it is possible to change in the future. Restricted Stock Unit and Performance Restricted Stock Unit Activities The following table summarizes RSUs and PRSUs activities for the fiscal year-to-date ended October 1, 2023 (in thousands, except share and per share amount). RSUs PRSUs Number of Weighted Average Number of Weighted Average Issued and unvested shares balances as of January 1, 2023 5,910,097 $ 14.11 1,461,061 $ 13.41 Granted 9,417,880 10.98 769,006 13.13 Vested (2,018,296) 13.29 (189,251) 13.41 Forfeited (1,245,122) 13.16 (1,503,136) 13.35 Issued and unvested shares outstanding as of October 1, 2023 12,064,559 $ 11.90 537,680 $ 13.17

Related Party

Related Party	9 Months Ended
	Oct. 01, 2023
Related Party Transactions [Abstract]
Related Party	Related Party Employment Relationship As of October 1, 2023, the Company employed two family members of the Company’s former Chief Executive Officer, who perform engineering work in the Fremont facility. Affiliate Notes On April 20, 2023, the Company issued $172.5 million aggregate principal amount of Convertible Senior Notes, which included $10.0 million principal amount of the Affiliate Notes that were issued to an entity affiliated with Thurman John “T.J.” Rodgers, the Company’s Chairman, in a concurrent private placement. The Affiliate Notes were recorded in Long-term debt, net on the Company’s Condensed Consolidated Balance Sheets. For the quarter and fiscal year-to-date ended October 1, 2023, the Company recorded $0.1 million of interest expense related to the Affiliate Notes in the Company’s Condensed Consolidated Statements of Operations. See Note 7 “Borrowings” for more information.

Variable Interest Entity

Variable Interest Entity	9 Months Ended
	Oct. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entity	Variable Interest Entity YBS Agreement On July 26, 2023, the Company entered into a manufacturing agreement (the “Agreement”) with YBS International Berhad (“YBS”), a Malaysia-based investment holding company with segments including electronic manufacturing and assembly, high-precision engineering, precision machining and stamping, among others. The Company and YBS agreed to share an initial investment of $100.0 million for the Gen2 Autoline 1 equipment and facilitation costs, as set out in the Agreement. Pursuant to the terms of the Agreement, the Company shall contribute 30% of the initial investment and YBS has the obligation to finance the remaining 70%. YBS assigned Orifast Solution Sdn Bhd (“OSSB”), a subsidiary, to manufacture lithium-ion batteries for Enovix under the terms and conditions of the Agreement. OSSB obtained $70.0 million of foreign currency term loan (the “Term Loan”) in financing for manufacturing operations under the Agreement from OCBC Bank (Malaysia) Berhad (“OCBC”). The Term Loan is expected to be repaid within six years with a 12 months grace period. Pricing under the Agreement is set on a cost-plus basis and the Company is subject to a minimum commitment pursuant to the Agreement. At any time during the first seven years of the Agreement’s term, the Company reserves the right to purchase the Gen2 Autoline 1 by repaying the equipment cost, net of depreciation, as defined in the Agreement. The Company also bears the early repayment penalty fee imposed by OCBC, if any. The term of the Agreement is for ten years and automatically extends for an additional five years. On September 13, 2023, the Company entered into a cash deposit agreement with OCBC to collateralize the Term Loan and the deposit will be placed in an interest-bearing account with an interest rate on par with the loan rate of the Term Loan. The Company will deposit sufficient collateral for the Term Loan. As of October 1, 2023, there is no outstanding balance of the Term Loan and no deposit was made to OCBC for the collateralization. Consolidated Variable Interest Entity

Acquisition

Acquisition	9 Months Ended
	Oct. 01, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisition	Acquisition On September 18, 2023, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Rene Limited, a corporation incorporated under the laws of the Republic of Korea (the “Seller”). On October 31, 2023, the Company closed the transaction contemplated by the Stock Purchase Agreement (the “Closing”) to purchase Routejade, Inc. (“Routejade”), a corporation incorporated under the laws of Republic of Korea. The total estimated purchase consideration of such transaction consists of cash consideration in the amount of approximately $15.8 million and 5,923,521 shares of common stock of the Company, par value $0.0001, for the purchase of substantially all of the outstanding shares of Routejade (the “Routejade Acquisition”). This acquisition constitutes a business acquisition under the accounting standard for business combinations and, therefore, will be accounted for as a business combination using the acquisition method of accounting. Goodwill from this acquisition is not expected to be deductible for tax purposes. The valuation of assets acquired and liabilities assumed are still being appraised by a third-party and as such, the purchase price allocation is not yet complete. For the quarter and fiscal year-to-date ended October 1, 2023, the Company recorded approximately $1.1 million of acquisition costs, which were included in Selling, general and administrative of the Condensed Consolidated Statements of Operations.

Restructuring Costs

Restructuring Costs	9 Months Ended
	Oct. 01, 2023
Restructuring and Related Activities [Abstract]
Restructuring Costs	Restructuring Costs Strategic Realignment of Fab1 On October 3, 2023, the Company announced that it initiated a strategic realignment of the Company’s first production line (“Fab1”) in Fremont designed to refocus the facility from a manufacturing hub to its “Center for Innovation,” focused on new product development, including a plan of workforce reduction. Currently, the Company expects this restructuring plan to be substantially completed in the fourth quarter of 2023. In connection with such strategic realignment, the Company recorded approximately $3.0 million of restructuring costs for the quarter and fiscal year-to-date ended October 1, 2023, which consisted of severance, termination benefits, stock-based compensation expense and inventory costs. These restructuring costs were reflected in Restructuring cost in the Condensed Consolidated Statements of Operations. As of October 1, 2023, the Company has not paid any of the restructuring costs and $2.1 million of the restructuring liability was included in Accrued compensation on the Condensed Consolidated Balance Sheet.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Oct. 01, 2023	Jul. 02, 2023	Apr. 02, 2023	Oct. 02, 2022	Jul. 03, 2022	Apr. 03, 2022	Oct. 01, 2023	Oct. 02, 2022
Pay vs Performance Disclosure
Net (loss) income	$ (16,185)	$ (64,306)	$ (73,603)	$ (82,013)	$ (1,135)	$ 42,707	$ (154,094)	$ (40,441)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Oct. 01, 2023 shares	Oct. 01, 2023 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Betsy Atkins [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		During the quarter ended October 1, 2023 , the Company’s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities set forth in the table below. Type of Trading Arrangement Name and Position Action Adoption/Termination Date Rule 10b5-1* Non-Rule 10b5-1** Total Shares of Common Stock to be Sold Total Shares of Common Stock to be Purchased Expiration Date (1) Betsy Atkins, Board of Director Adoption August 29, 2023 x 35,506 — December 26, 2024 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (1) The plan expires on December 26, 2024, or upon the earlier completion of all authorized transactions under the plan.
Name	Betsy Atkins
Title	Board of Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 29, 2023
Arrangement Duration	398 days
Aggregate Available	35,506	35,506

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 01, 2023
Accounting Policies [Abstract]
Basis of presentation	The accompanying condensed consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States (“GAAP”).The Condensed Consolidated Balance Sheet as of October 1, 2023, the Condensed Consolidated Statements of Operations, the Condensed Consolidated Statement of Comprehensive Income, the Condensed Consolidated Statements of Changes in Shareholders’ Equity and the Condensed Consolidated Statements of Cash Flows for the quarters and fiscal years-to-date ended October 1, 2023 and October 2, 2022 are unaudited. These accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC for interim financial reporting. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring items, considered necessary to present fairly the Company’s financial condition, results of operations, stockholders’ equity and cash flows for the periods presented above. The results of operations for the quarter and year-to-date ended October 1, 2023 are not necessarily indicative of the operating results for the full year, and therefore should not be relied upon as an indicator of future results. The Condensed Consolidated Balance Sheet as of January 1, 2023 included herein was derived from the audited consolidated financial statements as of that date and the accompanying consolidated financial statements and related notes are included in the Company’s Annual Report on Form 10-K.
Consolidation	The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the condensed consolidated financial statements and accompanying notes during the reporting periods. Estimates and assumptions include but are not limited to: depreciable lives for property and equipment, valuation for inventory, the valuation allowance on deferred tax assets, assumptions used in stock-based compensation, incremental borrowing rate for operating right-of-use assets and lease liabilities, and estimates to fair value common stock warrants. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances.
Investments	Investments The Company’s investments consist of highly liquid fixed-income securities. The Company determines the appropriate classification of its investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its investments as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, including prior to maturity. Investments with original maturities greater than 90 days and remaining maturities of less than one year are normally classified within current assets on the Condensed Consolidated Balance Sheets. In addition, investments with maturities beyond one year at the time of purchase that are highly liquid in nature and represent the investment of cash that is available for current operations are classified as current assets. Unrealized gains and losses on these investments are reported as a separate component of Accumulated other comprehensive loss until the security is sold, the security has matured, or the security has realized. Realized gains and losses on these investments are calculated based on the specific identification method and would be reclassified from Accumulated other comprehensive loss to Other income (expense), net in the Condensed Consolidated Statements of Operations.
Variable Interest Entity	Variable Interest Entity The Company determines at the inception of each arrangement whether an entity in which the Company holds an investment or in which the Company has other variable interests is considered a VIE. The Company consolidates the VIE’s balance sheet and results of operations into its condensed consolidated financials when the Company deems to be the primary beneficiary that meets both of the following criteria: (1) the Company has the power to direct activities that most significantly affect the VIE’s economic performance and (2) the Company has the obligation to absorb losses or the right to receive benefits of the VIE that in either case could potentially be significant to the VIE. The Company continually reassesses whether the Company is the primary beneficiary of a VIE for the consolidation analysis. If the Company is not the primary beneficiary in a VIE, the Company accounts for the investment or other variable interest in accordance with applicable GAAP. Please refer to Note 13 “Variable Interest Entity” for more details. The Company will reconsider whether the entity is still a VIE if certain reconsideration events occur as defined in the Accounting Standards Codification (“ASC”) 810, Consolidation,
Foreign Currency Transactions	Foreign Currency Transactions The functional currency of the Company’s international subsidiaries is the U.S. dollar. Monetary assets and liabilities of the Company's international subsidiaries that are denominated in foreign currency are remeasured into U.S. dollars at period-end exchange rates. Non-monetary assets and liabilities that are denominated in the foreign currency are remeasured into U.S. dollars at the historical rates. Foreign transaction gains and losses resulting from the conversion of the transaction currency to functional currency and remeasurement of foreign currency accounts are reflected in Other income (expense), net of the Condensed Consolidated Statements of Operations. For the quarter and fiscal year-to-date ended October 1, 2023, the Company recorded an immaterial amount of net foreign transaction gains in Other income (expense), net of the Condensed Consolidated Statements of Operations.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Oct. 01, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table details the fair value measurements of assets and liabilities that were measured at fair value on a recurring basis based on the following three-tiered fair value hierarchy per ASC 820, Fair Value Measurement , as of October 1, 2023 and January 1, 2023 (in thousands). Fair Value Measurement using Level 1 Level 2 Level 3 Total As of October 1, 2023 Assets: Cash equivalents: Money Market Funds $ 29,259 $ — $ — $ 29,259 Short-term investments: U.S. Treasuries — 100,522 — 100,522 Liabilities: Private Placement Warrants $ — $ — $ 44,940 $ 44,940 As of January 1, 2023 Assets: Cash equivalents: Money Market Funds $ 319,946 $ — $ — $ 319,946 Liabilities: Private Placement Warrants $ — $ — $ 49,080 $ 49,080
Schedule of Cash Equivalents and Short-term Investments	The following is a summary of cash equivalents and short-term investments (in thousands). Reported as Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Cash Equivalents Short-term Investments As of October 1, 2023 Money Market Funds $ 29,259 $ — $ — $ 29,259 $ 29,259 $ — U.S. Treasuries 100,535 2 (15) 100,522 — 100,522 Total $ 129,794 $ 2 $ (15) $ 129,781 $ 29,259 $ 100,522 As of January 1, 2023 Money Market Funds $ 319,946 $ — $ — $ 319,946 $ 319,946 $ —
Schedule of Changes in Fair Value for Level 3	The following tables summarize the changes for Level 3 items measured at fair value on a recurring basis using significant unobservable inputs (in thousands). Private Placement Warrants Fair value as of January 1, 2023 $ 49,080 Change in fair value (4,140) Fair value as of October 1, 2023 $ 44,940 Private Placement Warrants Fair value as of January 2, 2022 $ 124,260 Change in fair value (44,040) Fair value as of October 2, 2022 $ 80,220
Schedule of Key Assumptions used for determining Fair Value of Private Placement Warrants	The following table summarizes the key assumptions used for determining the fair value of the Private Placement warrants. Private Placement Warrants Outstanding as of October 1, 2023 Private Placement Warrants Outstanding as of January 1, 2023 Expected term (in years) 2.8 3.5 Expected volatility 90.0% 92.5% Risk-free interest rate 4.8% 4.2% Expected dividend rate 0.0% 0.0%

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Oct. 01, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment and Depreciation Expense	Property and equipment as of October 1, 2023 and January 1, 2023, consisted of the following (in thousands). October 1, 2023 January 1, 2023 Machinery and equipment $ 74,565 $ 55,694 Office equipment and software 2,412 1,586 Furniture and fixtures 829 771 Leasehold improvements 30,012 24,565 Construction in process 49,956 33,268 Total property and equipment 157,774 115,884 Less: accumulated depreciation (21,061) (12,016) Property and equipment, net $ 136,713 $ 103,868 The following table summarizes the depreciation and amortization expenses related to property and equipment, which are recorded within cost of revenue, research and development expense and selling, general and administrative expense in the Condensed Consolidated Statements of Operations (in thousands). Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Depreciation expense $ 3,588 $ 2,857 $ 10,566 $ 4,388

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Oct. 01, 2023
Inventory Disclosure [Abstract]
Schedule of Components of Inventory	Inventory consists of the following components (in thousands). October 1, 2023 January 1, 2023 Raw materials $ — $ 481 Work-in-process 15 106 Finished goods 200 47 Total inventory $ 215 $ 634

Lease (Tables)

Lease (Tables)	9 Months Ended
	Oct. 01, 2023
Leases [Abstract]
Schedule of Lease Cost and Supplemental Lease and Cash Flow Information	The components of lease costs were as follows (in thousands): Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Operating lease cost $ 478 $ 453 $ 1,428 $ 1,292 Supplemental lease information: As of Operating leases October 1, 2023 January 1, 2023 Weighted-average remaining lease term 6.9 years 7.7 years Weighted-average discount rate 6.8% 6.8% Supplemental cash flow information related to leases are as follows (in thousands): Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,053 $ 1,022
Schedule of Maturity of Lease Liabilities	The following is a schedule of maturities of lease liabilities as of October 1, 2023 (in thousands). Operating lease 2023 (remaining six months) $ 353 2024 1,449 2025 1,492 2026 1,491 2027 1,513 Thereafter 4,262 Total 10,560 Less: imputed interest (2,111) Present value of lease liabilities $ 8,449

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Oct. 01, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Dilute Net EPS of Common Stock	The following table sets forth the computation of the Company’s basic and diluted net EPS of common stock for the periods presented below (in thousands, except share and per share amount). Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Numerator: Net loss attributable to common stockholders - basic $ (16,185) $ (82,013) $ (154,094) $ (40,441) Decrease in fair value of Private Placement Warrants (31,320) — (4,140) (44,040) Net loss attributable to common stockholders - diluted $ (47,505) $ (82,013) $ (158,234) $ (84,481) Denominator: Weighted-average shares outstanding used in computing net loss per share of common stock, basic 159,829,716 153,332,007 157,559,138 152,497,010 Dilutive effect of Private Placement Warrants 1,541,701 — 701,255 1,276,261 Weighted-average shares outstanding used in computing net loss per share of common stock, diluted 161,371,417 153,332,007 158,260,393 153,773,271 Net loss per share of common stock: Basic $ (0.10) $ (0.53) $ (0.98) $ (0.27) Diluted $ (0.29) $ (0.53) $ (1.00) $ (0.55)
Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Loss Per Share	The following table discloses shares of the securities that were not included in the diluted EPS calculation above because they are anti-dilutive for the periods presented above. Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Stock options outstanding 3,075,138 5,083,643 3,075,138 5,083,643 Restricted stock units and performance restricted stock units outstanding 12,602,239 5,933,914 12,602,239 5,933,914 Assumed conversion of Convertible Senior Notes 11,053,800 — 6,608,868 — Private Placement Warrants outstanding — 6,000,000 — — Employee stock purchase plan estimated shares 243,474 380,847 243,474 380,847

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Oct. 01, 2023
Debt Disclosure [Abstract]
Schedule of Components of Long-Term Debt, Net	The Company’s long-term debt, net consists of the following (in thousands). Annual Interest Rate Maturity Date As of October 1, 2023 Convertible Senior Notes 3.0 % May 1, 2028 $ 172,500 Less: unamortized debt issuance costs (5,420) Long-term debt, net $ 167,080
Summary of Interest Expense Related to Convertible Notes	The following table summarizes the interest expenses related to Convertible Senior Notes, which are recorded within Interest expense in the Condensed Consolidated Statements of Operations (in thousands). October 1, 2023 Quarter Ended Fiscal Year-to-Date Ended Coupon interest $ 1,283 $ 2,326 Amortization of debt issuance costs 275 497 Total interest expense on Convertible Senior Notes $ 1,558 $ 2,823

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Oct. 01, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Total Stock-based Compensation Expense	The following table summarizes the total stock-based compensation expense, by operating expense category, recognized in the Condensed Consolidated Statements of Operations for the periods presented below (in thousands). Quarters Ended Fiscal Years-to-Date Ended October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022 Cost of revenue $ 2,396 $ 1,067 $ 5,001 $ 1,317 Research and development 4,949 3,372 22,072 9,705 Selling, general and administrative 5,929 4,260 30,400 11,095 Restructuring cost 359 — 359 — Total stock-based compensation expense $ 13,633 $ 8,699 $ 57,832 $ 22,117
Schedule of Stock Option Activity	The following table summarizes stock option activities for the fiscal year-to-date ended October 1, 2023 (in thousands, except share and per share amount). Number of Weighted Weighted Aggregate Intrinsic Value (1) (2) Balances as of January 1, 2023 5,034,282 $ 9.07 Exercised (1,135,249) 8.13 $ 13,446 Forfeited (823,895) 9.20 Balances as of October 1, 2023 3,075,138 $ 9.39 7.5 $ 11,166 (1) The intrinsic value of options exercised is based upon the value of the Company’s stock at exercise. (2) The aggregate intrinsic value of the stock options outstanding as of October 1, 2023 represents the value of the Company’s closing stock price at $12.55 on the last trading day of the quarter ended October 1, 2023 in excess of the exercise price multiplied by the number of options outstanding.
Schedule of RSUs and PRSUs Activity	The following table summarizes RSUs and PRSUs activities for the fiscal year-to-date ended October 1, 2023 (in thousands, except share and per share amount). RSUs PRSUs Number of Weighted Average Number of Weighted Average Issued and unvested shares balances as of January 1, 2023 5,910,097 $ 14.11 1,461,061 $ 13.41 Granted 9,417,880 10.98 769,006 13.13 Vested (2,018,296) 13.29 (189,251) 13.41 Forfeited (1,245,122) 13.16 (1,503,136) 13.35 Issued and unvested shares outstanding as of October 1, 2023 12,064,559 $ 11.90 537,680 $ 13.17

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 20, 2023	Apr. 30, 2023	Jul. 02, 2023	Oct. 01, 2023	Oct. 02, 2022	Jan. 01, 2023
Debt Instrument [Line Items]
Working capital				$ 331,600
Accumulated deficit				538,868		$ 384,774
Proceeds from issuance of Convertible Senior Notes				172,500	$ 0
Purchase of capped calls	$ 17,300		$ 17,300	$ 17,250	$ 0
3.0 % Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Principal balance		$ 172,500
Proceeds from issuance of Convertible Senior Notes		$ 166,600
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Interest rate		3%

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Oct. 01, 2023	Jan. 01, 2023
Private Placement Warrants
Liabilities:
Private Placement Warrants	$ 44,940	$ 49,080
Money Market Funds
Cash equivalents:
Cash Equivalents	29,259	319,946
U.S. Treasuries
Short-term investments
Short-term Investments	100,522
Level 1 | Private Placement Warrants
Liabilities:
Private Placement Warrants	0	0
Level 1 | Money Market Funds
Cash equivalents:
Cash Equivalents	29,259	319,946
Level 1 | U.S. Treasuries
Short-term investments
Short-term Investments	0
Level 2 | Private Placement Warrants
Liabilities:
Private Placement Warrants	0	0
Level 2 | Money Market Funds
Cash equivalents:
Cash Equivalents	0	0
Level 2 | U.S. Treasuries
Short-term investments
Short-term Investments	100,522
Level 3 | Private Placement Warrants
Liabilities:
Private Placement Warrants	44,940	49,080
Level 3 | Money Market Funds
Cash equivalents:
Cash Equivalents	0	$ 0
Level 3 | U.S. Treasuries
Short-term investments
Short-term Investments	$ 0

Fair Value Measurement - Cash E

Fair Value Measurement - Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands	Oct. 01, 2023	Jan. 01, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Amortized Cost	$ 129,794
Unrealized Gain	2
Unrealized Loss	(15)
Estimated Fair Value	129,781
Cash Equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated Fair Value	29,259
Short-term Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated Fair Value	100,522
Money Market Funds
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Amortized Cost	29,259	$ 319,946
Unrealized Gain	0
Unrealized Loss	0
Estimated Fair Value	29,259	319,946
Money Market Funds | Cash Equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated Fair Value	29,259	319,946
Money Market Funds | Short-term Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated Fair Value	0	$ 0
U.S. Treasuries
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Amortized Cost	100,535
Unrealized Gain	2
Unrealized Loss	(15)
Estimated Fair Value	100,522
U.S. Treasuries | Cash Equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated Fair Value	0
U.S. Treasuries | Short-term Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Estimated Fair Value	$ 100,522

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Oct. 01, 2023	Jan. 01, 2023	Dec. 05, 2021	Jul. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of the convertible senior notes	$ 183.3
Private Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding (in shares)	6,000,000	6,000,000		6,000,000
Exercise price of warrants (in dollars per share)			$ 11.50
Level 3 | Fair Value, Recurring | Private Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding (in shares)	6,000,000
Fair value of warrant per share (in dollars per share)	$ 7.49
Exercise price of warrants (in dollars per share)	$ 11.50

Fair Value Measurement - Sche_2

Fair Value Measurement - Schedule of Changes in Fair Value for Level 3 (Details) - Private Placement Warrants - Level 3 - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at beginning of period	$ 49,080	$ 124,260
Change in fair value	(4,140)	(44,040)
Fair value at end of period	$ 44,940	$ 80,220

Fair Value Measurement - Sche_3

Fair Value Measurement - Schedule of Key Assumptions used for Determining Fair Value of Private Placement Warrants (Details) - Private Placement Warrants outstanding	Oct. 01, 2023	Jan. 01, 2023
Expected term (in years)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Public placement warrants expiration term	2 years 9 months 18 days	3 years 6 months
Expected volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants, measurement input	0.900	0.925
Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants, measurement input	0.048	0.042
Expected dividend rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants, measurement input	0	0

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Oct. 01, 2023	Jan. 01, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 157,774	$ 115,884
Less: accumulated depreciation	(21,061)	(12,016)
Property and equipment, net	136,713	103,868
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	74,565	55,694
Office equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,412	1,586
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	829	771
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	30,012	24,565
Construction in process
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 49,956	$ 33,268

Property and Equipment - Sche_2

Property and Equipment - Schedule of Depreciation Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,588	$ 2,857	$ 10,566	$ 4,388

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended			9 Months Ended
	Oct. 01, 2023	Jul. 02, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022	Jan. 01, 2023
Property, Plant and Equipment [Abstract]
Impairment of equipment	$ 0	$ 4,400,000	$ 0	$ 4,411,000	$ 0
Accrued impairment charges	$ 600,000			$ 600,000		$ 1,700,000

Inventory - Summary (Details)

Inventory - Summary (Details) - USD ($) $ in Thousands	Oct. 01, 2023	Jan. 01, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 481
Work-in-process	15	106
Finished goods	200	47
Total inventory	$ 215	$ 634

Inventory - Narrative (Details)

Inventory - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Inventory Disclosure [Abstract]
Inventory write off	$ 600,000	$ 0	$ 600,000	$ 0

Leases - Additional Information

Leases - Additional Information (Details)	Mar. 31, 2021
Leases [Abstract]
Option to extend, term	5 years

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Leases [Abstract]
Operating lease cost	$ 478	$ 453	$ 1,428	$ 1,292

Leases - Supplemental Lease Inf

Leases - Supplemental Lease Information (Details)	Oct. 01, 2023	Jan. 01, 2023
Leases [Abstract]
Weighted-average remaining lease term	6 years 10 months 24 days	7 years 8 months 12 days
Weighted-average discount rate	6.80%	6.80%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related To Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,053	$ 1,022

Leases - Schedule of Maturity o

Leases - Schedule of Maturity of Lease Liabilities (Details) $ in Thousands	Oct. 01, 2023 USD ($)
Operating lease
2023 (remaining six months)	$ 353
2024	1,449
2025	1,492
2026	1,491
2027	1,513
Thereafter	4,262
Total	10,560
Less: imputed interest	(2,111)
Present value of lease liabilities	$ 8,449

Net Loss per Share - Computatio

Net Loss per Share - Computation of Basic and Dilute Net EPS of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Numerator:
Net loss attributable to common stockholders - basic	$ (16,185)	$ (82,013)	$ (154,094)	$ (40,441)
Decrease in fair value of Private Placement Warrants	(31,320)	0	(4,140)	(44,040)
Net loss attributable to common stockholders - diluted	$ (47,505)	$ (82,013)	$ (158,234)	$ (84,481)
Denominator:
Weighted-average shares outstanding used in computing net loss per share of common stock, basic (in shares)	159,829,716	153,332,007	157,559,138	152,497,010
Dilutive effect of Private Placement Warrants (in shares)	1,541,701	0	701,255	1,276,261
Weighted-average shares outstanding used in computing net loss per share of common stock, diluted (in shares)	161,371,417	153,332,007	158,260,393	153,773,271
Net loss per share of common stock:
Basic (in dollars per share)	$ (0.10)	$ (0.53)	$ (0.98)	$ (0.27)
Diluted (in dollars per share)	$ (0.29)	$ (0.53)	$ (1)	$ (0.55)

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Stock options outstanding
Subsidiary Sale Of Stock [Line Items]
Anti-dilutive securities	3,075,138	5,083,643	3,075,138	5,083,643
Restricted stock units and performance restricted stock units outstanding
Subsidiary Sale Of Stock [Line Items]
Anti-dilutive securities	12,602,239	5,933,914	12,602,239	5,933,914
Assumed conversion of Convertible Senior Notes
Subsidiary Sale Of Stock [Line Items]
Anti-dilutive securities	11,053,800	0	6,608,868	0
Private Placement Warrants outstanding
Subsidiary Sale Of Stock [Line Items]
Anti-dilutive securities	0	6,000,000	0	0
Employee stock purchase plan estimated shares
Subsidiary Sale Of Stock [Line Items]
Anti-dilutive securities	243,474	380,847	243,474	380,847

Borrowings - Components of Long

Borrowings - Components of Long-Term Debt, Net (Details) - USD ($) $ in Thousands	Oct. 01, 2023	Apr. 30, 2023
Debt Instrument [Line Items]
Less: unamortized debt issuance costs	$ (5,420)
Long-term debt, net	167,080
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Annual Interest Rate		3%
Long-term debt, gross	$ 172,500

Borrowings - Additional Informa

Borrowings - Additional Information (Details)		1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 20, 2023 USD ($) day $ / shares	Apr. 30, 2023 USD ($)	Oct. 01, 2023 USD ($) $ / shares	Jul. 02, 2023 USD ($)	Oct. 01, 2023 USD ($) $ / shares	Oct. 02, 2022 USD ($)	Apr. 17, 2023 $ / shares	Jan. 01, 2023 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of Convertible Senior Notes					$ 172,500,000	$ 0
Purchase of capped calls	$ 17,300,000			$ 17,300,000	17,250,000	0
Debt issuance cost incurred					5,251,000	$ 0
Accrued interest			$ 2,300,000		$ 2,300,000			$ 0
Share price (in dollars per share) | $ / shares			$ 12.55		$ 12.55
Common Stock
Debt Instrument [Line Items]
Share price (in dollars per share) | $ / shares							$ 13.57
Capped Call Transaction
Debt Instrument [Line Items]
Cap price (in dollars per share)	21.17
Capped Call Transaction | Common Stock
Debt Instrument [Line Items]
Cap price premium percentage over share price	56%
3.0 % Convertible Senior Notes
Debt Instrument [Line Items]
Conversion price (in dollars per share) | $ / shares	$ 15.61
3.0 % Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Principal balance		$ 172,500,000
Proceeds from issuance of Convertible Senior Notes		$ 166,600,000
Conversion ratio	0.0640800
Redemption price, percentage of principal	100%
Minimum principal amount outstanding not subject to partial redemption	$ 100,000,000
Debt issuance cost incurred			$ 0		$ 5,900,000
3.0 % Convertible Senior Notes | Convertible Debt | Debt Conversion Condition One
Debt Instrument [Line Items]
Threshold trading days | day	20
Threshold consecutive trading days | day	30
Threshold percentage of stock price trigger	130%
3.0 % Convertible Senior Notes | Convertible Debt | Debt Conversion Condition Two
Debt Instrument [Line Items]
Threshold trading days | day	5
Threshold consecutive trading days | day	10
Threshold percentage of stock price trigger	98%
Purchase Option | Convertible Debt
Debt Instrument [Line Items]
Principal balance	$ 22,500,000
Affiliate Notes | Convertible Debt | Related Party
Debt Instrument [Line Items]
Principal balance	$ 10,000,000
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Interest rate		3%

Borrowings - Interest Expenses

Borrowings - Interest Expenses Related to Convertible Senior Notes (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Oct. 01, 2023	Oct. 01, 2023	Oct. 02, 2022
Debt Instrument [Line Items]
Amortization of debt issuance costs		$ 497	$ 0
3.0 % Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Coupon interest	$ 1,283	2,326
Amortization of debt issuance costs	275	497
Total interest expense on Convertible Senior Notes	$ 1,558	$ 2,823

Commitments and Contingencies (

Commitments and Contingencies (Details)	Jan. 25, 2023 plaintiff	Jan. 21, 2022 plaintiff	Oct. 01, 2023 USD ($)	Jan. 01, 2023 USD ($)
Loss Contingencies [Line Items]
Purchase commitments			$ 73,700,000	$ 22,700,000
Deferred revenue			3,800,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-02
Loss Contingencies [Line Items]
Expected time of satisfaction, amount			$ 0
Expected timing of satisfaction, period			12 months
Sopheak Prak & Ricardo Pimentel v Enovix
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff		2
Securities Class Action Compliant
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff	2

Warrants (Details)

Warrants (Details) - $ / shares	Oct. 01, 2023	Jan. 01, 2023	Dec. 05, 2021	Jul. 31, 2021
Common Stock Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)				17,500,000
Public Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	0	0		11,500,000
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	6,000,000	6,000,000		6,000,000
Each whole private placement warrant became exercisable for Number of whole shares (in shares)			1
Exercise price of warrants (in dollars per share)			$ 11.50

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Total Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 13,633	$ 8,699	$ 57,832	$ 22,117
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,396	1,067	5,001	1,317
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	4,949	3,372	22,072	9,705
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	5,929	4,260	30,400	11,095
Restructuring cost
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 359	$ 0	$ 359	$ 0

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Oct. 01, 2023	Oct. 01, 2023	Oct. 02, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation capitalized		$ 800,000	$ 1,200,000
Unrecognized tax benefit		0	$ 0
Unrecognized stock-based compensation expenses related to nonvested equity awards	$ 140,100,000	$ 140,100,000
Weighted average period of recognition for unrecognized stock-based compensation related to nonvested equity awards		3 years 10 months 24 days
Incremental stock based compensation expenses		$ 21,100,000
Common Stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Issuance of common stock subject to return (in shares)	1,304,954
Estimated loss associated with common stock issuance	$ 22,400,000	22,400,000
Equity Awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Accrued bonuses to be settled in equity awards	0	0
Employee stock purchase plan estimated shares
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized stock-based compensation expenses related to nonvested equity awards	$ 500,000	$ 500,000
Weighted average period of recognition for unrecognized stock-based compensation related to nonvested equity awards		1 year 1 month 6 days
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares remained subject to right of repurchase (in shares)		657,981

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Oct. 01, 2023
Number of Options Outstanding
Beginning balance (in shares)	5,034,282
Exercised (in shares)	(1,135,249)
Forfeited (in shares)	(823,895)
Ending balance (in shares)	3,075,138
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 9.07
Exercised (in dollars per share)	8.13
Forfeited (in dollars per share)	9.20
Ending balance (in dollars per share)	$ 9.39
Weighted Average Remaining Contractual Life (Years)
Outstanding balance	7 years 6 months
Aggregate Intrinsic Value
Exercised	$ 13,446
Outstanding, balance	$ 11,166
Share price (in dollars per share)	$ 12.55

Stock-based Compensation - RSUs

Stock-based Compensation - RSUs and PRSUs Activity (Details)	9 Months Ended
	Oct. 01, 2023 $ / shares shares
RSUs
Number of Shares Outstanding
Issued and unvested shares beginning balances (in shares) | shares	5,910,097
Granted (in shares) | shares	9,417,880
Vested (in shares) | shares	(2,018,296)
Forfeited (in shares) | shares	(1,245,122)
Issued and unvested shares outstanding ending balance (in shares) | shares	12,064,559
Weighted Average Grant Date Fair Value
Issued and unvested shares beginning balances (in dollars per share) | $ / shares	$ 14.11
Granted (in dollars per share) | $ / shares	10.98
Vested (in dollars per share) | $ / shares	13.29
Forfeited (in dollars per share) | $ / shares	13.16
Issued and unvested shares outstanding ending balance (in dollars per share) | $ / shares	$ 11.90
PRSUs
Number of Shares Outstanding
Issued and unvested shares beginning balances (in shares) | shares	1,461,061
Granted (in shares) | shares	769,006
Vested (in shares) | shares	(189,251)
Forfeited (in shares) | shares	(1,503,136)
Issued and unvested shares outstanding ending balance (in shares) | shares	537,680
Weighted Average Grant Date Fair Value
Issued and unvested shares beginning balances (in dollars per share) | $ / shares	$ 13.41
Granted (in dollars per share) | $ / shares	13.13
Vested (in dollars per share) | $ / shares	13.41
Forfeited (in dollars per share) | $ / shares	13.35
Issued and unvested shares outstanding ending balance (in dollars per share) | $ / shares	$ 13.17

Related Party (Details)

Related Party (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Oct. 01, 2023 USD ($) family_member	Oct. 01, 2023 USD ($) family_member	Apr. 30, 2023 USD ($)	Apr. 20, 2023 USD ($)
3.0 % Convertible Senior Notes | Convertible Debt
Related Party Transaction [Line Items]
Principal balance			$ 172,500
Interest expense	$ 1,558	$ 2,823
Related Party
Related Party Transaction [Line Items]
Number of employed family members | family_member	2	2
Related Party | Affiliate Notes
Related Party Transaction [Line Items]
Interest expense	$ 100	$ 100
Related Party | Affiliate Notes | Convertible Debt
Related Party Transaction [Line Items]
Principal balance				$ 10,000

Variable Interest Entity (Detai

Variable Interest Entity (Details) $ in Millions	Jul. 26, 2023 USD ($)
Orifast Solution Sdn Bhd
Variable Interest Entity [Line Items]
Finance receivable	$ 70
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Variable Interest Entity [Line Items]
Initial investment	$ 100
Percentage of initial investment to be paid by each party	30%
Term of agreement	10 years
Additional term of agreement	5 years
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum
Variable Interest Entity [Line Items]
Term of right reserved to purchase the equipment	7 years
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | YBS International Berhad (YBS)
Variable Interest Entity [Line Items]
Percentage of initial investment to be paid by each party	70%
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Orifast Solution Sdn Bhd
Variable Interest Entity [Line Items]
Term loan repaid period	6 years
Grace period	12 months

Acquisition (Details)

Acquisition (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	9 Months Ended
	Oct. 31, 2023	Oct. 01, 2023	Oct. 01, 2023	Jan. 01, 2023
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.0001
Routejade, Inc.
Business Acquisition [Line Items]
Acquisition costs		$ 1.1	$ 1.1
Routejade, Inc. | Subsequent Event
Business Acquisition [Line Items]
Total estimated purchase consideration	$ 15.8
Common stock consideration (in shares)	5,923,521
Common stock, par value (in dollars per share)	$ 0.0001

Restructuring Costs (Details)

Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Restructuring and Related Activities [Abstract]
Restructuring cost	$ 3,021	$ 0	$ 3,021	$ 0
Restructuring reserve	2,100		2,100
Expected cost remaining	$ 36,000		$ 36,000